服務(wù)熱線
13817140470
產(chǎn)品分類
8-OHdG抗體說明書
更新時間：2012-05-24 瀏覽次數(shù)：6228
| 在生命科學(xué)試劑方面，我們代理諸多歐美等：sigma，amresco,bachem,abcam,merck,millipore,abgent, Chemicon, R&D, BD,bender,biovision，ENZO，CST, Biosource, Life Technologies，F(xiàn)itzgerald, Biodesign, serotec, Biolegend，F(xiàn)ermentas，Qiagen，signagen等。我們密切國內(nèi)外的科研進展，為您提供高質(zhì)量的產(chǎn)品和專業(yè)的服務(wù)！ 您對產(chǎn)品有任何問題，可以通過,,與我們公司，我們確保您在zui短時間內(nèi)得到滿意的回復(fù)。我們將不斷提供新產(chǎn)品和新技術(shù)資料，并將借助網(wǎng)絡(luò)平臺，以讓您能夠認(rèn)識我們公司，了解我們的產(chǎn)品，獲得。 本公司： ： 何 |
BACKGROUND
DNA or RNA damage can hinder the ability of a cell to carry out its function and can significantly increase the likelihood of tumor formation. One of the causes of damaged DNA and RNA is oxidation of the bases. 8hydroxy2'deoxyguanosine, 8hydroxyguanine （8OHdG） and 8hydroxyguanosine are all markers of oxidative damage to RNA and DNA. 8hydroxy2'deoxyguanosine is produced by reactive oxygen and nitrogen species, including hydroxyl radical and peroxynitrite. 8hydroxyguanine is one of the major base lesions involved in mutagenesis and is caused by ionizing radiation and radiomimetic agents. 8hydroxyguanosine induces a transversion of G to T in DNA, which may be mutagenic. Markers of DNA and RNA damage are useful research tools when studying the effects of this type of damage.
REFERENCES
1. Musarrat, J., et al. 1996. Prognostic and aetiological relevance of 8hydroxyguanosine in human breast carcinogenesis. Eur. J. Cancer 32: 12091214
2. Parker, A.R., et al. 2002. 8hydroxyguanosine repair is defective in some microsalite stable colorectal cancer cells. Cancer Res. 62: 72307233.
3. Abe, T., et al. 2002. Alteration of 8hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson’s disease. Neurosci. Lett. 336: 105108.
4. Winter, D.B., et al. 2003. Normal somatic hypermutation of Ig genes in the absence of 8hydroxyguanineDNA glycosylase. J. Immunol. 170: 55585562.
5. Russo, M.T., et al. 2004. Accumulation of the oxidative base lesion 8hydroxyguanine in DNA of tumorprone mice defective in both the MYH and OGG1 DNA glycosylases. Cancer Res. 64: 44114414.
6. Okugawa, Y., et al. 2006. UVAinduced degradation of 8hydroxyguanine in oligonucleotide and the effect on its activities in yeast oligonucleotide transformation assay. Nucleic Acids Symp. Ser. 48: 287288.
7. Watanabe, E., et al. 2006. Significance of 8hydroxy2'deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy. J. Card. Fail. 12: 527532.
8. Noblitt, S.D., et al. 2007. The role of metal ion binding in generating 8hydroxy2'deoxyguanosine from the nucleoside 2'deoxyguanosine and the nucleotide 2'deoxyguanosine5'monophosphate. J. Inorg. Biochem.
101: 536542.
9. Kuo, H.W., et al. 2007. Urinary 8hydroxy2'deoxyguanosine （8OHdG） and genetic polymorphisms in breast cancer patients. Mutat. Res. 631: 6268.
APPLICATIONS
8OHdG （J1） is recommended for detection of 8OHdG modified proteins by Western Blotting （starting dilution 1:200, dilution range 1:1001:1000）, immunofluorescence （starting dilution 1:50, dilution range 1:501:500） and solid phase ELISA （starting dilution 1:30, dilution range 1:301:3000）.
RESEARCH USE
For research use only, not for use in diagnostic procedures.
RECOMMENDED SECONDARY REAGENTS
To ensure optimal results, the following support （secondary） reagents are recommended: 1） Western Blotting: use goat antirabbit IgGHRP: sc2004 （dilution range: 1:20001:100,000） or Cruz Marker™ compatible goat antirabbit IgGHRP: sc2030 （dilution range: 1:20001:5000）, Cruz Marker™ Molecular Weight Standards: sc2035, TBS Blotto A Blocking Reagent: sc2333 and Western Blotting Luminol Reagent: sc2048. 2） Immunofluorescence: use goat antirabbit IgGFITC: sc2012 （dilution range: 1:1001:400） or goat antirabbit IgGTR: sc2780 （dilution range: 1:1001:400） with UltraCruz™ Mounting Medium: sc24941.
- (上一篇)：植酸鈉說明書
- (下一篇)：小鼠白細胞介素12（IL-12）試劑盒說明書
